From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer

DEBU TRIPATHY
PUBLISHED: 5:26 PM, WED JUNE 5, 2013
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.



Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
Cancer: Advice for Dealing With the Financial Burden
Hear financial expert and registered nurse Mary Ann Cagle discuss the financial burden of cancer, often a result of expensive treatments, appointments, and diagnostic tests. Learn where to look for possible financial support.
$auto_registration$